January 30, 2023 11:32 AM ESTUpdated February 7, 09:28 AM

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

John Carroll

Editor & Founder

Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

#JPM23: Reg­u­la­to­ry un­cer­tain­ty? What about M&A? Da­ta rule? Alessan­dro Masel­li and John Car­roll take out their crys­tal balls

John Carroll

Editor & Founder

Sign up to read this article for free.

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study